Recent advances: the cytochrome P450 enzymes
- PMID: 7663035
- DOI: 10.1177/106002809502900612
Recent advances: the cytochrome P450 enzymes
Abstract
Successful application of information on cytochrome P450 to prevent drug interactions and improve the therapeutic risk: benefit ratio can occur only if we know which enzyme is responsible for the metabolism of a drug. Until recently, this information was not usually available when new drugs reached the market. It is not enough to know the fraction of a dose metabolized versus excreted unchanged or the metabolic pathways by which a compound is degraded. Studies conducted during drug development must identify the enzyme or enzymes involved in the metabolism of new drugs. In addition, the ability of new drugs to inhibit or induce the activity of the key P450 enzymes must be known if we are to take full advantage of our current knowledge of how the cytochrome P450 system works.
Similar articles
-
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".Clin Pharmacol Ther. 2000 Oct;68(4):375-83. doi: 10.1067/mcp.2000.109519. Clin Pharmacol Ther. 2000. PMID: 11061577
-
Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.Ther Drug Monit. 1996 Aug;18(4):393-6. doi: 10.1097/00007691-199608000-00014. Ther Drug Monit. 1996. PMID: 8857557
-
Drug metabolism and variability among patients in drug response.N Engl J Med. 2005 May 26;352(21):2211-21. doi: 10.1056/NEJMra032424. N Engl J Med. 2005. PMID: 15917386 Review. No abstract available.
-
Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.J Gend Specif Med. 2002 Jan-Feb;5(1):25-33. J Gend Specif Med. 2002. PMID: 11859684 Review.
-
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".Clin Pharmacol Ther. 2003 Nov;74(5):437-47. doi: 10.1016/S0009-9236(03)00229-7. Clin Pharmacol Ther. 2003. PMID: 14586384 Clinical Trial.
Cited by
-
Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9.Microb Cell Fact. 2021 Apr 26;20(1):90. doi: 10.1186/s12934-021-01577-4. Microb Cell Fact. 2021. PMID: 33902608 Free PMC article.
-
Deep sequencing analysis to identify novel and rare variants in pain-related genes in patients with acute postoperative pain and high morphine use.J Pain Res. 2019 Sep 19;12:2755-2770. doi: 10.2147/JPR.S213869. eCollection 2019. J Pain Res. 2019. PMID: 31571979 Free PMC article.
-
Does differing metabolism by cytochrome p450 have clinical importance?Curr Atheroscler Rep. 2000 Jan;2(1):14-9. doi: 10.1007/s11883-000-0090-4. Curr Atheroscler Rep. 2000. PMID: 11122720 Review.
-
Antiarrhythmic agents: drug interactions of clinical significance.Drug Saf. 2000 Dec;23(6):509-32. doi: 10.2165/00002018-200023060-00003. Drug Saf. 2000. PMID: 11144659 Review.
-
Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.Br J Clin Pharmacol. 2006 Feb;61(2):200-10. doi: 10.1111/j.1365-2125.2005.02540.x. Br J Clin Pharmacol. 2006. PMID: 16433874 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources